The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Phase I trial of decitabine plus ipilimumab in R/R MDS & AML
Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a Phase I trial (NCT02890329) of decitabine (DAC) in combination with ipilimumab (IPI) in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML), with or without prior allogeneic hematopoietic cell transplantation (allo-HCT). The trial investigated whether decitabine, a hypomethylating agent, increased the efficacy of CTLA-4 blockade with IPI, and what impact alloreactivity had on the outcomes. The study showed promising response rates in this pretreated population, with immune-related toxicities occurring in line with previous observations of IPI use. Superior clinical activity was seen in patients who were transplant-naïve, compared to the post-allo-HCT arm, indicating that an alloreactive setting is not needed for CTLA-4 blockade benefit. The trial is ongoing to further confirm the efficacy and safety of the novel combination. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
